Author: onur

January 10, 2023

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief Commercial Officer

November 2, 2022

Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel

October 24, 2022

Neurotech Chief Medical Officer authors article in Ophthalmology Times

A roadmap to preserving the prime years of patients diagnosed with MacTel, was published by Ophthalmology Times and written by Thomas Aaberg, Jr., explores the progression of MacTel and the… read more

July 20, 2022

Neurotech Chief Medical Officer authors article in The Ophthalmologist

The article, A Tiny Factory: Scaffolding a solution to macular telangiectasia with encapsulated cell therapy, was published by The Ophthalmologist and written by Thomas Aaberg, Jr., explores how ECT can… read more

October 31, 2021

Neurotech Pharmaceuticals Appoints Thomas Aaberg Jr., M.D. as Chief Medical Officer

June 17, 2017

Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia.

April 29, 2016

Neurotech Announces Renewed Focus on NT-501 (CNTF) Encapsulated Cell Therapy Clinical Programs.

November 2, 2013

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implant

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases by Kauper et al.

August 6, 2013

James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals.